ACHE and early-onset autosomal dominant Alzheimer disease: In drug discovery programs, AChE inhibitors are of great interest for treatment of cholinergic deficiencies in the PNS (e.g. myasthenia gravis) and CNS (e.g. Alzheimer's disease).